Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

BEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in April 2026. Ocular plans to present additional data and analyses from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD).

• Symposium Title: Redefining the Management of Neovascular AMDSymposium Date/Time: Saturday, April 11, 2026, 1:15 – 2:00 PM PDTPresenters: Jeffrey S. Heier, MD, Chief Scientific Officer at Ocular Therapeutix, Peter K. Kaiser, MD, Chief Development Officer at Ocular Therapeutix, and Andrew A. Moshfeghi, MD, MBA, FASRS, USC Roski Eye Institute

A copy of the VBS symposium presentation will be made available on Ocular’s website following the presentation on Saturday, April 11, 2026.

• Presentation Title: What are TKIs and What Do They Do?Session: SARyV: Macular Diseases (SARyV: Enfermedades maculares)Session Date/Time: Wednesday, April 15, 2026, 10:35 – 10:50 AM ART (UTC-3)Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO at Ocular Therapeutix

• Presentation Title: Current State of Treatment of Diabetic Retinal DiseaseSession: Current state of treatment of diabetic retinal diseaseSession Date/Time: Wednesday, April 15, 2026, 1:30 – 1:45 PM ART (UTC-3)Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO at Ocular Therapeutix

• Presentation Title: Current State of Treatment of Neovascular AMDSession: Wet AMD: The Debate (DMAE Húmeda: el debate)Session Date/Time: Wednesday, April 15, 2026, 3:45 – 4:00 PM ART (UTC-3)Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO at Ocular Therapeutix

Exact medical conference presentation times may be subject to change.

Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA®is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.